333 related articles for article (PubMed ID: 11384606)
21. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat.
Zorrilla EP; Valdez GR; Nozulak J; Koob GF; Markou A
Brain Res; 2002 Oct; 952(2):188-99. PubMed ID: 12376179
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress.
Pelleymounter MA; Joppa M; Ling N; Foster AC
J Pharmacol Exp Ther; 2002 Jul; 302(1):145-52. PubMed ID: 12065711
[TBL] [Abstract][Full Text] [Related]
23. CRF type 1 receptors of the medial amygdala modulate inhibitory avoidance responses in the elevated T-maze.
Vicentini JE; Céspedes IC; Nascimento JO; Bittencourt JC; Viana MB
Horm Behav; 2014 Mar; 65(3):195-202. PubMed ID: 24472740
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats.
Qi X; Guzhva L; Yang Z; Febo M; Shan Z; Wang KKW; Bruijnzeel AW
Eur Neuropsychopharmacol; 2016 Sep; 26(9):1378-1389. PubMed ID: 27461514
[TBL] [Abstract][Full Text] [Related]
25. The serotonergic projection from the median raphe nucleus to the ventral hippocampus is involved in the retrieval of fear memory through the corticotropin-releasing factor type 2 receptor.
Ohmura Y; Izumi T; Yamaguchi T; Tsutsui-Kimura I; Yoshida T; Yoshioka M
Neuropsychopharmacology; 2010 May; 35(6):1271-8. PubMed ID: 20072117
[TBL] [Abstract][Full Text] [Related]
26. Anxiety states induced by post-weaning social isolation are mediated by CRF receptors in the dorsal raphe nucleus.
Bledsoe AC; Oliver KM; Scholl JL; Forster GL
Brain Res Bull; 2011 May; 85(3-4):117-22. PubMed ID: 21396988
[TBL] [Abstract][Full Text] [Related]
27. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats.
Basso AM; Spina M; Rivier J; Vale W; Koob GF
Psychopharmacology (Berl); 1999 Jul; 145(1):21-30. PubMed ID: 10445369
[TBL] [Abstract][Full Text] [Related]
28. The influence of CRF and alpha-helical CRF(9-41) on rat fear responses, c-Fos and CRF expression, and concentration of amino acids in brain structures.
Skórzewska A; Bidziński A; Hamed A; Lehner M; Turzyńska D; Sobolewska A; Maciejak P; Szyndler J; Wisłowska-Stanek A; Płaźnik A
Horm Behav; 2008 Nov; 54(5):602-12. PubMed ID: 18601929
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor.
Ho SP; Takahashi LK; Livanov V; Spencer K; Lesher T; Maciag C; Smith MA; Rohrbach KW; Hartig PR; Arneric SP
Brain Res Mol Brain Res; 2001 Apr; 89(1-2):29-40. PubMed ID: 11311973
[TBL] [Abstract][Full Text] [Related]
30. Increased anxiety-like behavior of rats during amphetamine withdrawal is reversed by CRF2 receptor antagonism.
Vuong SM; Oliver HA; Scholl JL; Oliver KM; Forster GL
Behav Brain Res; 2010 Mar; 208(1):278-81. PubMed ID: 19958793
[TBL] [Abstract][Full Text] [Related]
31. Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor.
DeVries AC; Pert A
Psychopharmacology (Berl); 1998 Jun; 137(4):333-40. PubMed ID: 9676892
[TBL] [Abstract][Full Text] [Related]
32. Persistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.
Gutman DA; Owens MJ; Thrivikraman KV; Nemeroff CB
Neuropharmacology; 2011 Jun; 60(7-8):1135-41. PubMed ID: 20951149
[TBL] [Abstract][Full Text] [Related]
33. Similar effect of CRF
Spinieli RL; Leite-Panissi CRA
Brain Res Bull; 2018 Mar; 137():187-196. PubMed ID: 29246866
[TBL] [Abstract][Full Text] [Related]
34. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
35. Microinjection of different doses of corticotropin-releasing factor into the medial prefrontal cortex produces effects opposing anxiety-related behavior in rats.
Ohata H; Shibasaki T
J Nippon Med Sch; 2011; 78(5):286-92. PubMed ID: 22041875
[TBL] [Abstract][Full Text] [Related]
36. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor.
Valdez GR; Roberts AJ; Chan K; Davis H; Brennan M; Zorrilla EP; Koob GF
Alcohol Clin Exp Res; 2002 Oct; 26(10):1494-501. PubMed ID: 12394282
[TBL] [Abstract][Full Text] [Related]
37. Hippocampal serotonergic system is involved in anxiety-like behavior induced by corticotropin-releasing factor.
Kagamiishi Y; Yamamoto T; Watanabe S
Brain Res; 2003 Nov; 991(1-2):212-21. PubMed ID: 14575894
[TBL] [Abstract][Full Text] [Related]
38. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
[TBL] [Abstract][Full Text] [Related]
39. The activation and blockage of CRF type 2 receptors of the medial amygdala alter elevated T-maze inhibitory avoidance, an anxiety-related response.
Alves SW; Portela NC; Silva MS; Céspedes IC; Bittencourt JC; Viana MB
Behav Brain Res; 2016 May; 305():191-7. PubMed ID: 26965566
[TBL] [Abstract][Full Text] [Related]
40. Dorsomedial hypothalamus CRF type 1 receptors selectively modulate inhibitory avoidance responses in the elevated T-maze.
Silva MS; Pereira BA; Céspedes IC; Nascimento JO; Bittencourt JC; Viana MB
Behav Brain Res; 2014 Sep; 271():249-57. PubMed ID: 24937051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
